Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Provectus Biopharmaceuticals Inc (NYSE MKT LLC:PVCT)

Delayed Data
As of Feb 10
 +0.014 / +3.17%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Provectus Biopharmaceuticals, Inc. manufactures prescription drugs, medical device systems and counter products. It is a development-stage biopharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company developing and intend to license or market and sell their two prescription drug candidates, PV-10, which is for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer; and PH-10, which provides minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. Through its subsidiaries, hold patents and other intellectual property related to OTC products and non-core technologies. Provectus Biopharmaceuticals was founded on January 17, 2002 and is headquartered in Knoxville, TN.

Contact Information

Provectus Biopharmaceuticals, Inc.
7327 Oak Ridge Highway
Knoxville Tennessee 37931-3488
P:(866) 594-5999
Investor Relations:



Individual stakeholders5.90%
Other institutional3.29%
Mutual fund holders2.00%

Top Executives

H. Craig DeesChairman & Chief Executive Officer
Timothy C. ScottPresident & Director
Peter R. CulpepperCOO, CFO, Secretary & Treasure
Eric A. WachterChief Technology Officer